PMID- 31360066
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D 
      axis.
PG  - 5405-5414
LID - 10.2147/OTT.S207542 [doi]
AB  - BACKGROUND: Long noncoding RNA (lncRNA) deleted in lymphocytic leukemia 1 (DLEU1) 
      was reported to be involved in the development and progression of multiple 
      cancers. However, the accurate expression pattern, biological function and 
      potential molecular mechanism of DLEU1 in glioma are not yet known. The present 
      study investigated the role of DLEU in the development and progression of glioma, 
      as well as the potential mechanism played by DLEU1 in glioma. MATERIALS AND 
      METHODS: The levels of DLEUI in glioma tissues and cell lines were examined using 
      quantitative real-time PCR. The potential effects of DLEU1 on the proliferation, 
      mobility, invasion and apoptosis of glioma cells were evaluated using 
      corresponding in vitro experiments. The association between DLEU1 and microRNA 
      (miR)-421 was also determined using luciferase reporter activity and RNA 
      immunoprecipitation (RIP) assays. RESULTS: The results revealed that DLEU1 was 
      significantly upregulated in glioma tissues and cell lines. Increased DLEU1 was 
      positively associated with the high-grade carcinoma (III-IV). Functional studies 
      revealed that knockdown of DLEU1 expression by siRNA led to decreased 
      proliferation, migration and invasion and increased apoptosis in human glioma 
      cells. Furthermore, luciferase reporter activity and RIP assays confirmed that 
      DLEUI could act as a competing endogenous RNA (ceRNA) for miR-421 that functioned 
      as a tumor suppressor in glioma. Moreover, inhibition miR-421 partially restored 
      the effect of DLEU1 knockdown on the glioma cells. DLEU1 could regulate myocyte 
      enhancer factor 2D (MEF2D) expression, a known target of miR-421 in glioma cells. 
      CONCLUSION: Taken together, these findings suggested that DLEU1 regulated MEF2D 
      expression to promote glioma progression by sponging miR-421 and that DLEU1 might 
      be a potential therapeutic target for glioma.
FAU - Feng, Li
AU  - Feng L
AD  - Department of Radiotherapy, China-Japan Union Hospital of Jilin University, 
      Changchun 130033, People's Republic of China.
FAU - He, Mingyuan
AU  - He M
AD  - Department of Radiotherapy, China-Japan Union Hospital of Jilin University, 
      Changchun 130033, People's Republic of China.
FAU - Rao, Min
AU  - Rao M
AD  - Department of Gastroenterology, The First Hospital of Jilin University, Changchun 
      130021, People's Republic of China.
FAU - Diao, Jiandong
AU  - Diao J
AD  - Department of Oncology and Hematology, China-Japan Union Hospital of Jilin 
      University, Changchun 130033, People's Republic of China.
FAU - Zhu, Yonggang
AU  - Zhu Y
AD  - Department of Radiotherapy, China-Japan Union Hospital of Jilin University, 
      Changchun 130033, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20190708
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
RIN - Onco Targets Ther. 2021 Sep 09;14:4735-4736. PMID: 34526776
PMC - PMC6625645
OTO - NOTNLM
OT  - DLEU1
OT  - LncRNA
OT  - MEF2D
OT  - glioma
OT  - miR-421
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/07/31 06:00
MHDA- 2019/07/31 06:01
PMCR- 2019/07/08
CRDT- 2019/07/31 06:00
PHST- 2019/03/04 00:00 [received]
PHST- 2019/06/05 00:00 [accepted]
PHST- 2019/07/31 06:00 [entrez]
PHST- 2019/07/31 06:00 [pubmed]
PHST- 2019/07/31 06:01 [medline]
PHST- 2019/07/08 00:00 [pmc-release]
AID - 207542 [pii]
AID - 10.2147/OTT.S207542 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Jul 8;12:5405-5414. doi: 10.2147/OTT.S207542. eCollection 
      2019.